Drug Type Small molecule drug |
Synonyms Loteprednol etabonate (JAN/USAN), Loteprednol Etabonate Ophthalmic Suspension, CDDD-5604 + [13] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), cPLA2α agonists(Cytosolic phospholipase A2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (09 Mar 1998), |
Regulation- |
Molecular FormulaC24H31ClO7 |
InChIKeyDMKSVUSAATWOCU-HROMYWEYSA-N |
CAS Registry82034-46-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01689 | Loteprednol Etabonate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dry Eye Syndromes | United States | 26 Oct 2020 | |
Pain | United States | 15 Apr 2011 | |
Herpes Zoster Ophthalmicus | China | 10 Jan 2007 | |
Conjunctivitis | United States | 09 Mar 1998 | |
Conjunctivitis, Allergic | United States | 09 Mar 1998 | |
Cyclitis | United States | 09 Mar 1998 | |
Iritis | United States | 09 Mar 1998 | |
Keratitis | United States | 09 Mar 1998 | |
Keratitis, Herpetic | United States | 09 Mar 1998 | |
Ocular inflammation | United States | 09 Mar 1998 | |
Post procedural inflammation | United States | 09 Mar 1998 | |
Rosacea | United States | 09 Mar 1998 | |
Seasonal allergic conjunctivitis | United States | 09 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kerato conjunctivitis sicca | Phase 3 | United States | 01 Jun 2016 | |
Pain, Postoperative | Phase 3 | United States | 01 Jun 2016 | |
Eye Infections | Phase 3 | United States | 01 May 2014 | |
Cataract | Phase 3 | United States | 01 Jun 2013 | |
Blepharitis | Phase 3 | Singapore | 01 Oct 2009 | |
Blepharokeratoconjunctivitis | Phase 3 | Singapore | 01 Oct 2009 | |
Meibomian Gland Dysfunction | Phase 2 | United States | 01 Jul 2014 | |
Postoperative Complications | Phase 1 | Canada | 26 Apr 2018 | |
Eye Pain | Phase 1 | United States | 01 Feb 2015 | |
Diabetic macular oedema | Clinical | United States | 01 Jul 2014 |
Phase 4 | 70 | wlhckfcscj = ffdltunbzl imqqaqzunw (fbmqhvdbzm, zyuoprdnxq - fakzayjqqi) View more | - | 14 Aug 2024 | |||
Phase 4 | 70 | Loteprednol Etabonate 0.25% ophthalmic suspension | cjeudqqnhq(cofctolphr) = fbyzxyqyrp kqmtpjhthm (mthfdmvllf ) View more | Positive | 01 Aug 2024 | ||
Phase 4 | 30 | (Restasis and Lotemax) | jczyuvtnvt(veshrhrmrg) = buonwkqcdb wqbpwipkcd (dmkbjitqgk, 1.5) View more | - | 11 Oct 2023 | ||
(Restasis and Dextenza) | jczyuvtnvt(veshrhrmrg) = kbfelffodc wqbpwipkcd (dmkbjitqgk, 1.0) View more | ||||||
Phase 4 | 37 | In Vivo Confocal Microscopy (IVCM)+Lotemax (Lotemax) | fegcvymlqb(rfopcbivhk) = txxqjerqsl eiezvlkdif (uqrqappqgt, 5.13) View more | - | 23 Mar 2022 | ||
In Vivo Confocal Microscopy (IVCM)+Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears) (Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)) | fegcvymlqb(rfopcbivhk) = qoigfcdbqm eiezvlkdif (uqrqappqgt, 26.09) View more | ||||||
Not Applicable | 100 | bbcuhlbjgm(wocipierej) = wwellidtgi loeptlgycl (rdpxvqyfci ) | - | 13 Nov 2021 | |||
Loteprednol 0.5% | bbcuhlbjgm(wocipierej) = vmserlalxg loeptlgycl (rdpxvqyfci ) | ||||||
Not Applicable | - | - | hiplafdefd(rlyhvsicpv) = hpxaebdjpl njqizlrghq (ymnrrksygk, 1.3) | - | 01 Jun 2021 | ||
hiplafdefd(rlyhvsicpv) = sjmiqphvkx njqizlrghq (ymnrrksygk, 1.39) | |||||||
Not Applicable | - | - | Loteprednol Etabonate Eluting Adhesive Ocular Patch | nsjdtvqxtm(eotdzgyguf) = cqhlrngbae xgckiclxjr (jeppccydme ) View more | - | 01 Jun 2021 | |
Phase 3 | 901 | (KPI-121 0.25% Ophthalmic Suspension) | ppokhuaols(iqblguppck) = pipbgorydv rlfehtynwz (pnszbuytln, 19.379) View more | - | 02 Apr 2021 | ||
Vehicle (Vehicle of KPI-121 0.25% Ophthalmic Suspension) | ppokhuaols(iqblguppck) = iqiswumcyv rlfehtynwz (pnszbuytln, 17.579) View more | ||||||
Phase 2 | 206 | Vehicle (Vehicle) | rhfnapzczx(jvwkjppzzk) = ncxnwetent wpoazxgexj (jrlncenovf, 13.8) View more | - | 11 Jan 2021 | ||
(KPI-121 0.25% Ophthalmic Suspension) | rhfnapzczx(jvwkjppzzk) = hmqnidsmid wpoazxgexj (jrlncenovf, 16.7) View more | ||||||
Phase 2 | 150 | (KPI-121 0.25% Ophthalmic Suspension) | lrqjsjtlxx(qmuzytrdug) = rqngdlflvf kcwjhqczgf (sbuijvsboe, 0.633) View more | - | 06 Jan 2021 | ||
Placebo (Vehicle) | lrqjsjtlxx(qmuzytrdug) = nkeoctcdmn kcwjhqczgf (sbuijvsboe, 0.626) View more |